Crucell N.V., an integrated biopharmaceutical company, focuses on the development, production, and marketing of vaccines and antibodies to prevent or treat infectious diseases. Its paediatric product portfolio comprises Quinvaxem, a liquid vaccine for five childhood diseases; Epaxal Junior, a hepatitis A vaccine; Hepavax-Gene, a vaccine against hepatitis B; and MoRu-Viraten, a vaccine for protection against measles and rubella. The company also markets various travel and endemic vaccines, such as Epaxal, an aluminum-free hepatitis A vaccine; Vivotif, the oral anti-typhoid vaccine; and Dukoral, an oral cholera vaccine. Its respiratory products include Inflexal, a virosome-adjuvanted vaccine for influenza. In addition, Crucell N.V. licenses various proprietary technologies, such as the PER.C6, a human designer cell line for the development and manufacturing of biopharma products; AdVac, which is used in combination with PER.C6 to develop recombinant vaccines; MAbstract for the discovery of drug targets and identification of human antibodies; STAR that is designed for the production yields of recombinant human antibodies and proteins on mammalian cell lines; Virosome, a vehicle enabling the use of virus antigens in the making of vaccinations; and Hansenula polymorpha expression system technology, which is used as a basis for developing and manufacturing new vaccines. Further, the company's products under development include vaccines against yellow fever, influenza, ebola, HIV, malaria, tuberculosis, human monoclonal antibodies against rabies, H5N1 antibodies, and pandemic influenza virus, as well as blood coagulation factors. Crucell N.V. markets its products through own sales force and distribution partners in Europe, North America, and Asia. Its strategic partners comprise DSM Biologics, Novartis, MedImmune, Merck, sanofi Pasteur, and Wyeth. The company was founded in 1993 and is based in Leiden, the Netherlands.